首页 > 最新文献

Transfusion science最新文献

英文 中文
Systematic RBC leucodepletion in France: where are we after six months? 法国系统性红细胞白细胞减少:6个月后进展如何?
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00012-6
Maurice Masse
{"title":"Systematic RBC leucodepletion in France: where are we after six months?","authors":"Maurice Masse","doi":"10.1016/S0955-3886(00)00012-6","DOIUrl":"10.1016/S0955-3886(00)00012-6","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 57-59"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00012-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Selective or universal leucodepletion: the Italian experience 选择性或普遍的白细胞减少:意大利的经验
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00015-1
Patrizia Accorsi, Antonio Iacone
{"title":"Selective or universal leucodepletion: the Italian experience","authors":"Patrizia Accorsi, Antonio Iacone","doi":"10.1016/S0955-3886(00)00015-1","DOIUrl":"10.1016/S0955-3886(00)00015-1","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 65-67"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00015-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Current position on preparation and quality of leucodepleted platelet concentrates for clinical use 临床用去白细胞血小板浓缩物的制备和质量现状
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00025-4
J Seghatchian, P Krailadsiri

Double dose leucodepleted PC without filtration is considered to be the most cost-effective way of preparing leucodepleted PC in a reasonable time. The procedure lends itself to a multicomponent system and production of hyperconcentrate and dry platelets, with <10–15 ml plasma in final product and viral inactivation without considerable loss of in vitro platelet functions.

Platelet concentrates obtained by various procedures are highly heterogeneous, even if a standard protocol is used for the preparation. Therefore, standard/standardisation in both production and testing procedures remain a challenging area in order to obtain comparative results.

Attention needs to be focused on growing and complex technical features of preparation and on the use of new filter material in terms of biocompatibility and the related effects of activated factors on function of platelets and leucocytes. Both the production process and storage containers appear to contribute to various cellular lesion and generation of some biological response modifiers such as complements, cytokines and microparticles. In this respect it is relevant to adopt a multiparameter analysis for the validation of platelet quality as some markers of platelet storage lesion have different affinity to various surfaces, leading to false under estimation.

Further development work is still needed in preparation and usage of dry platelet, platelet alternative and bacterially safe products.

The underlying conditions of the transfused patients is also an important issue in this respect, it is interesting to note that patients with high IL8 levels have a substantially lower platelet recovery.

在合理的时间内制备无过滤的双剂量贫铀PC被认为是最经济有效的方法。该方法适用于多组分系统和生产高浓缩血小板和干血小板,最终产品中有10-15 ml血浆,病毒灭活,体外血小板功能没有明显损失。通过各种程序获得的血小板浓缩物是高度不均匀的,即使使用标准方案进行制备。因此,为了获得比较结果,生产和测试程序的标准/标准化仍然是一个具有挑战性的领域。需要把注意力集中在制备的不断增长和复杂的技术特点上,以及在生物相容性和活化因子对血小板和白细胞功能的相关影响方面使用新的过滤材料。生产过程和储存容器似乎都有助于各种细胞损伤和产生一些生物反应调节剂,如补体、细胞因子和微粒。在这方面,采用多参数分析来验证血小板质量是有意义的,因为一些血小板储存损伤的标记物对不同表面有不同的亲和力,导致错误的估计。在制备和使用干血小板、替代血小板和细菌安全产品方面还需要进一步的开发工作。输血患者的基础条件也是这方面的一个重要问题,有趣的是,高il - 8水平的患者血小板恢复明显较低。
{"title":"Current position on preparation and quality of leucodepleted platelet concentrates for clinical use","authors":"J Seghatchian,&nbsp;P Krailadsiri","doi":"10.1016/S0955-3886(00)00025-4","DOIUrl":"10.1016/S0955-3886(00)00025-4","url":null,"abstract":"<div><p>Double dose leucodepleted PC without filtration is considered to be the most cost-effective way of preparing leucodepleted PC in a reasonable time. The procedure lends itself to a multicomponent system and production of hyperconcentrate and dry platelets, with &lt;10–15 ml plasma in final product and viral inactivation without considerable loss of in vitro platelet functions.</p><p>Platelet concentrates obtained by various procedures are highly heterogeneous, even if a standard protocol is used for the preparation. Therefore, standard/standardisation in both production and testing procedures remain a challenging area in order to obtain comparative results.</p><p>Attention needs to be focused on growing and complex technical features of preparation and on the use of new filter material in terms of biocompatibility and the related effects of activated factors on function of platelets and leucocytes. Both the production process and storage containers appear to contribute to various cellular lesion and generation of some biological response modifiers such as complements, cytokines and microparticles. In this respect it is relevant to adopt a multiparameter analysis for the validation of platelet quality as some markers of platelet storage lesion have different affinity to various surfaces, leading to false under estimation.</p><p>Further development work is still needed in preparation and usage of dry platelet, platelet alternative and bacterially safe products.</p><p>The underlying conditions of the transfused patients is also an important issue in this respect, it is interesting to note that patients with high IL8 levels have a substantially lower platelet recovery.</p></div>","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 85-88"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00025-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Leucocyte fragments in ‘prestorage-leucodepleted’ blood products: a qualitative analysis 白细胞碎片在“储存前-白细胞缺失”血液制品:定性分析
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00019-9
M Sivakumaran , P Saunders , D Hanmer , M Drury , J Seghatchian
{"title":"Leucocyte fragments in ‘prestorage-leucodepleted’ blood products: a qualitative analysis","authors":"M Sivakumaran ,&nbsp;P Saunders ,&nbsp;D Hanmer ,&nbsp;M Drury ,&nbsp;J Seghatchian","doi":"10.1016/S0955-3886(00)00019-9","DOIUrl":"10.1016/S0955-3886(00)00019-9","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 81-82"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00019-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Patent report 专利报告
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(99)00128-9
{"title":"Patent report","authors":"","doi":"10.1016/S0955-3886(99)00128-9","DOIUrl":"https://doi.org/10.1016/S0955-3886(99)00128-9","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Page IX"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(99)00128-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92002178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent report 专利报告
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(99)00125-3
{"title":"Patent report","authors":"","doi":"10.1016/S0955-3886(99)00125-3","DOIUrl":"https://doi.org/10.1016/S0955-3886(99)00125-3","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Page VIII"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(99)00125-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92007689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distribution of normal prion protein in blood 正常朊病毒蛋白在血液中的分布
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00010-2
Ian MacGregor, Olive Drummond, Marc Turner, Robin Barclay, Chris Prowse
{"title":"Distribution of normal prion protein in blood","authors":"Ian MacGregor,&nbsp;Olive Drummond,&nbsp;Marc Turner,&nbsp;Robin Barclay,&nbsp;Chris Prowse","doi":"10.1016/S0955-3886(00)00010-2","DOIUrl":"10.1016/S0955-3886(00)00010-2","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Page 51"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00010-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Leucofiltration of sickle cell trait blood “the blocker”: NBS London & S.E. experience 镰状细胞特征血“阻滞剂”的白细胞过滤:NBS伦敦和S.E.的经验
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00017-5
M.J Beard, J Seghatchian, R Cardigan, J Bennett, K.M Smith, L Williamson
{"title":"Leucofiltration of sickle cell trait blood “the blocker”: NBS London & S.E. experience","authors":"M.J Beard,&nbsp;J Seghatchian,&nbsp;R Cardigan,&nbsp;J Bennett,&nbsp;K.M Smith,&nbsp;L Williamson","doi":"10.1016/S0955-3886(00)00017-5","DOIUrl":"10.1016/S0955-3886(00)00017-5","url":null,"abstract":"","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 71-73"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00017-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Management of cold agglutination syndrome 寒凝综合征的处理
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00032-1
Terry Hamblin

Cold haemagglutination syndrome is difficult to treat. Fortunately it seldom needs treating. In most cases cold agglutinins are an incidental finding representing either normality or a benign chronic monoclonal gammopathy that does not cause ill health. Two sorts of symptoms are likely in the more severe cases. Acrocyanosis is usually treated by keeping the patient warm and if necessary removing him or her to Florida or the Canary Islands. In the rare cases of haemolytic anaemia, an underlying lymphoid tumour should be sought and treated. If none exists, then it is unlikely that the treatments that are useful in warm antibody haemolytic anaemia will be helpful. Plasma exchange ought to work but in practice there are frequently problems of red cell agglutination within the cell separator or the plastic tubes. For this reason plasma exchange within a heated room is advocated. When cardiac surgery is contemplated pre-operative plasma exchange is sometimes helpful, or the heart may be stopped by potassium solutions and the operation is carried out in the warm.

感冒血凝综合征是一种难以治疗的疾病。幸运的是,它很少需要治疗。在大多数情况下,冷凝集素是偶然发现的,代表正常或良性慢性单克隆γ病,不会导致健康不良。更严重的病例可能出现两种症状。肢青症的治疗方法通常是让病人保持温暖,必要时将他或她转移到佛罗里达或加那利群岛。在罕见的溶血性贫血病例中,应寻找并治疗潜在的淋巴样肿瘤。如果不存在,那么对热抗体溶血性贫血有用的治疗方法就不太可能起作用。血浆交换应该是有效的,但在实际操作中,在细胞分离器或塑料管内经常存在红细胞凝集的问题。因此,提倡在加热的房间内进行等离子体交换。当考虑进行心脏手术时,术前血浆交换有时是有帮助的,或者心脏可能会因钾溶液而停止,手术在温暖的环境中进行。
{"title":"Management of cold agglutination syndrome","authors":"Terry Hamblin","doi":"10.1016/S0955-3886(00)00032-1","DOIUrl":"10.1016/S0955-3886(00)00032-1","url":null,"abstract":"<div><p>Cold haemagglutination syndrome is difficult to treat. Fortunately it seldom needs treating. In most cases cold agglutinins are an incidental finding representing either normality or a benign chronic monoclonal gammopathy that does not cause ill health. Two sorts of symptoms are likely in the more severe cases. Acrocyanosis is usually treated by keeping the patient warm and if necessary removing him or her to Florida or the Canary Islands. In the rare cases of haemolytic anaemia, an underlying lymphoid tumour should be sought and treated. If none exists, then it is unlikely that the treatments that are useful in warm antibody haemolytic anaemia will be helpful. Plasma exchange ought to work but in practice there are frequently problems of red cell agglutination within the cell separator or the plastic tubes. For this reason plasma exchange within a heated room is advocated. When cardiac surgery is contemplated pre-operative plasma exchange is sometimes helpful, or the heart may be stopped by potassium solutions and the operation is carried out in the warm.</p></div>","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 121-124"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00032-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21620380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Comparison of platelet immunity in patients with SLE and with ITP SLE与ITP患者血小板免疫的比较
Pub Date : 2000-02-01 DOI: 10.1016/S0955-3886(00)00004-7
Alan H Lazarus , Janet Ellis , John W Semple , Meera Mody , Andrew R Crow , John Freedman

Idiopathic thrombocytopenic purpura (ITP) is characterized by the development of a specific anti-platelet autoantibody immune response mediating the development of thrombocytopenia. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of a wide variety of autoantibodies. In 15–20% of SLE cases, patients develop thrombocytopenia which appears to be autoimmune in nature (SLE-TP). To better understand the pathogenesis of the thrombocytopenia associated with SLE, we investigated the overlapping platelet and cellular immune features between SLE and ITP. Thirty-one patients with SLE, eight with SLE-TP, and 17 with ITP, were studied and compared to 60 healthy controls. We evaluated platelet-associated IgG, platelet microparticles, reticulated platelets, platelet HLA-DR expression, in vivo cytokine levels, lymphocyte proliferation, and the T lymphocyte anti-platelet immune response in these patients. Patients with SLE-TP and those with ITP had increased platelet-associated IgG, an increased percentage of platelet microparticles, a higher percentage of reticulated platelets and larger platelets, suggesting antibody-mediated platelet destruction and increased platelet production. More than 50% of patients with ITP had increased HLA-DR on their platelet surface whereas subjects with SLE-TP did not. Analysis of serum cytokines demonstrated increased levels of IL-10, IL-15 and TNF-α in patients with SLE, but in those with ITP, only increased levels of IL-15 were seen, no increases in any of these cytokines were observed in patients with in SLE-TP. The ability of lymphocytes to proliferate in response to phorbol myristate acetate (PMA) stimulation was increased in SLE-TP, but was normal in both SLE and ITP. Lymphocytes from subjects with ITP displayed an increased ability to proliferate on exposure to platelets, in contrast, those with SLE-TP did not. While the number of subjects evaluated with SLE-TP was small, these data reveal a number of differences in the immunopathogenesis between SLE-TP and ITP.

特发性血小板减少性紫癜(ITP)的特点是发展特异性抗血小板自身抗体免疫反应介导血小板减少的发展。系统性红斑狼疮(SLE)是一种自身免疫性疾病,其特点是产生多种自身抗体。在15-20%的SLE病例中,患者出现血小板减少症,这似乎是自身免疫性的(SLE- tp)。为了更好地了解与SLE相关的血小板减少的发病机制,我们研究了SLE和ITP之间重叠的血小板和细胞免疫特征。研究了31例SLE患者,8例SLE- tp患者,17例ITP患者,并与60名健康对照进行了比较。我们评估了这些患者的血小板相关IgG、血小板微粒、网状血小板、血小板HLA-DR表达、体内细胞因子水平、淋巴细胞增殖和T淋巴细胞抗血小板免疫反应。slep - tp患者和ITP患者的血小板相关IgG增加,血小板微粒百分比增加,网状血小板百分比更高,血小板更大,提示抗体介导的血小板破坏和血小板生成增加。超过50%的ITP患者血小板表面HLA-DR升高,而slep患者则没有。血清细胞因子分析显示,SLE患者IL-10、IL-15和TNF-α水平升高,但在ITP患者中,仅观察到IL-15水平升高,在SLE- tp患者中未观察到任何这些细胞因子的升高。在SLE- tp患者中,淋巴细胞对肉豆酸盐佛波酯(PMA)刺激的增殖能力增加,而在SLE和ITP患者中则是正常的。ITP患者的淋巴细胞暴露于血小板后增殖能力增强,而slep患者则没有。虽然接受slep - tp评估的受试者数量很少,但这些数据揭示了slep - tp和ITP在免疫发病机制上的许多差异。
{"title":"Comparison of platelet immunity in patients with SLE and with ITP","authors":"Alan H Lazarus ,&nbsp;Janet Ellis ,&nbsp;John W Semple ,&nbsp;Meera Mody ,&nbsp;Andrew R Crow ,&nbsp;John Freedman","doi":"10.1016/S0955-3886(00)00004-7","DOIUrl":"10.1016/S0955-3886(00)00004-7","url":null,"abstract":"<div><p>Idiopathic thrombocytopenic purpura (ITP) is characterized by the development of a specific anti-platelet autoantibody immune response mediating the development of thrombocytopenia. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of a wide variety of autoantibodies. In 15–20% of SLE cases, patients develop thrombocytopenia which appears to be autoimmune in nature (SLE-TP). To better understand the pathogenesis of the thrombocytopenia associated with SLE, we investigated the overlapping platelet and cellular immune features between SLE and ITP. Thirty-one patients with SLE, eight with SLE-TP, and 17 with ITP, were studied and compared to 60 healthy controls. We evaluated platelet-associated IgG, platelet microparticles, reticulated platelets, platelet HLA-DR expression, in vivo cytokine levels, lymphocyte proliferation, and the T lymphocyte anti-platelet immune response in these patients. Patients with SLE-TP and those with ITP had increased platelet-associated IgG, an increased percentage of platelet microparticles, a higher percentage of reticulated platelets and larger platelets, suggesting antibody-mediated platelet destruction and increased platelet production. More than 50% of patients with ITP had increased HLA-DR on their platelet surface whereas subjects with SLE-TP did not. Analysis of serum cytokines demonstrated increased levels of IL-10, IL-15 and TNF-<em>α</em> in patients with SLE, but in those with ITP, only increased levels of IL-15 were seen, no increases in any of these cytokines were observed in patients with in SLE-TP. The ability of lymphocytes to proliferate in response to phorbol myristate acetate (PMA) stimulation was increased in SLE-TP, but was normal in both SLE and ITP. Lymphocytes from subjects with ITP displayed an increased ability to proliferate on exposure to platelets, in contrast, those with SLE-TP did not. While the number of subjects evaluated with SLE-TP was small, these data reveal a number of differences in the immunopathogenesis between SLE-TP and ITP.</p></div>","PeriodicalId":80242,"journal":{"name":"Transfusion science","volume":"22 1","pages":"Pages 19-27"},"PeriodicalIF":0.0,"publicationDate":"2000-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0955-3886(00)00004-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21621729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 41
期刊
Transfusion science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1